Upstart Holdings Inc vs Zoetis Inc — how do they compare? Upstart Holdings Inc trades at $26.01 (market cap $2.52B), while Zoetis Inc trades at $73.65 (market cap $30.29B). The key difference: Zoetis Inc is far larger — about 12× Upstart Holdings Inc's market cap, and Zoetis Inc pays a 2.89% dividend while Upstart Holdings Inc pays none. Which is the better fit depends on your goals.
| UPST | ZTS | |
|---|---|---|
Market Cap | $2.52B | $30.29B |
Sector | Financials | Health |
52-Week High | $68.11 | $150.61 |
52-Week Low | $24.22 | $71.91 |
Enterprise Value | — | $37.86B |
Dividend Yield | — | 2.89% |
Signals from Pluang's Aura AI — not financial advice
Upstart Holdings (UPST) trades at $26.98, down 3.81% on the day, reflecting recent bearish momentum amid mixed earnings performance. The stock shows oversold technical signals with an RSI of 18.98, while fundamentals highlight a return to profitability in 2025 with net income of $53.60M on $1.02B revenue. Recent news indicates strategic refocus on personal loans and AI-driven lending growth, though cash flow volatility and high debt levels pose concerns. Analyst consensus remains divided with a $45.00 price target suggesting significant upside potential from current levels.
The outlook for UPST hinges on execution in AI-powered lending expansion and margin improvement, with risks including consumer credit stress and competitive pressures. Institutional sentiment is cautiously optimistic, but investors should monitor debt management and quarterly earnings consistency for sustained recovery.
Zoetis (ZTS) trades at $73.6, down 2.92% on the day, near its 52-week low amid bearish technical signals. The stock shows strong fundamentals with a P/E of 12, net margin of 27.69%, and consistent earnings beats, but faces headwinds from weak U.S. companion animal sales and reduced 2026 guidance. Recent news includes an FDA emergency use authorization for Simparica Trio and participation in healthcare conferences.
The outlook is mixed: valuation appears attractive with a consensus price target of $93.40, but near-term risks include competitive pressures and soft pet health demand. Long-term investors may find value in its profitability and market dominance, though volatility persists from sector challenges and investor sentiment shifts.
Trailing returns across standard periods
Latest headlines on both assets
Upstart Holdings Inc provides credit services. The company provides a proprietary, cloud-based, artificial intelligence lending platform. The platform aggregates consumer demand for loans and connects it to the network of Upstart AI-enabled bank partners. The revenue of the company is primarily comprised of fees paid by banks.
Read more on UPST →Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Read more on ZTS →